Services Tysabri Drug Supplier

Tysabri Drug Supplier

Derek Clarke is a reputable Tysabri drug supplier.

Tsyabri (natalizumab, Biogen Idec) is indicated for adults with relapsing forms of multiple sclerosis (MS). It is administered by a healthcare professional as a monthly infusion.

Tysabri is available for:


  • ‘aggressive multiple sclerosis’ – people who have had two or more disabling relapses in one year, and an increase in lesions as shown on an MRI scan
  • people who have had an increase in the number or severity of relapses while taking another drug

Tysabri is an antibody that prevents certain immune cells from leaving the blood stream and entering the brain and spinal cord which, in MS, causes inflammation and damage.

A two-year study showed that people on Tysabri had a 67% reduction in the number of relapses, compared to what would be expected if no treatment had been taken.

Tysabri also slowed the accumulation of disability over two years. Only 17% of people taking the drug had worse disability, compared with 29% of people on placebo.

The drug is generally well tolerated but can cause side-effects, including progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal infection.

PML (progressive multifocal leukoencephalopathy) is caused by a viral infection in the brain and can lead to death or disability. Several people treated with Tysabri have died because of PML. Analysis of the number of cases of PML suggests that about 1 in every 500 people treated with Tysabri are at risk of developing the infection.

It is important that professionals and patients are aware of the risks of PML, recognise the early signs and know what to do if they notice these signs.

Longer-term benefits of Tysabri are unknown.

Derek Clarke, with more than 30 years as experience as an exporter of both branded and generics drugs, is able to source and supply products, often unavailable through other sources, quickly and efficiently.  

For more information on our Tysabri drug supplies please contact us on

+44 (0) 208 952 2061